Navigation Links
Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
Date:1/6/2011

OKLAHOMA CITY, Jan. 6, 2011 /PRNewswire/ -- Altheus Therapeutics, Inc., announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa™ Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis.  No serious adverse events were experienced by patients in this study.  "We are excited to have achieved this milestone, as it prepares Altheus to begin our planned Phase II clinical program to definitively evaluate the safety and efficacy of Zoenasa in ulcerative colitis patients," commented Dennis Schafer, President and CEO of Altheus.

Nearly 1.2 million Americans suffer from inflammatory bowel disease. The two most common forms, ulcerative colitis and Crohn's disease, are chronic lifelong conditions which significantly impact the quality of life. Front-line treatment for ulcerative colitis is monotherapy with oral or rectal mesalamine.  However many patients do not achieve remission and must escalate to more expensive and risky treatments.

Zoenasa is a novel combination of two FDA-approved drugs with well established efficacy and safety records that have been shown to act synergistically for the treatment of ulcerative colitis.  In animal models of colitis, Zoenasa resolved inflammation more rapidly and completely than standard mesalamine treatment.  Zoenasa Rectal Suspension is being investigated for the treatment of left-sided ulcerative colitis, which affects approximately 80% of ulcerative colitis patients.  The U.S. Food and Drug Administration has granted Zoenasa orphan designation for the treatment of pediatric ulcerative colitis.  An oral formulation of Zoenasa is in pre-clinical development.

Altheus Therapeutics, Inc., of Oklahoma City, is a pharmaceutical development company focused on innovative therapies for the treatment of inflammatory bowel disease. Contact:Dennis Schafer, CEOdschafer@altheustherapeutics.com(405) 319-8180
'/>"/>

SOURCE Altheus Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 2016 Research and Markets has announced the ... 2017 - MedCore" report to their offering. ... , , The cerebrospinal ... In healthy individuals, it is circulated though the brain and its ventricles, ... amount of CSF surrounding the brain changes significantly. ...
(Date:11/30/2016)... Research and Markets has announced the addition of the ... their offering. ... Detachable coil embolization is a minimally invasive method ... embolization treatment of cerebral aneurysms is less invasive and requires less recovery ... wall of an artery in the brain. This area bulges in the ...
(Date:11/30/2016)... 2016 Varian Medical Systems (NYSE: ... JUST Company in the Healthcare Equipment and Services industry, ... inaugural "JUST 100 List." The rankings are based on ... conducted on attitudes towards corporate behavior, involving 50,000 Americans ... U.S companies against their peers within 32 major industries. ...
Breaking Medicine Technology:
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, ... ... today, featuring an inspirational interview of two ostomy patients, standing as living proof ... million people suffer from digestive diseases and issues that spike around the holidays. ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, ... entry through labeling, storing, shipping and disposal. The new version is a faster ...
(Date:12/2/2016)... Wexford, PA (PRWEB) , ... December 02, 2016 , ... ... manages stress and overall health, day and night. No other wearable health technology on ... management. We wanted to give poeple more meaningful insights about their health than ...
(Date:12/2/2016)... ... December 02, 2016 , ... On November 24th, 2016, ... from eight different sites throughout Miami-Dade and Broward counties. This is the largest ... hard on Thanksgiving morning by putting together individual meals via assembly lines and ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
Breaking Medicine News(10 mins):